Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 13/20 | 0.65 |
| ▸ | CHRNA4 | P43681 | 13/20 | 0.65 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.65 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.65 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.65 |
| ▸ | CHRNB4 | P30926 | 3/20 | 0.37 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL900113 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL4058865 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL335652 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL6339022 | 1.00 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL23410453 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL13518560 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| Hydrochloric Acid SCHEMBL16212072 | 0.98 | CHRNB2 (0.62) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL12356559 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL1008776 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 | |
| SCHEMBL13050975 | 0.83 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNA3CHRNB3CHRNA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3802539-B1 | TETRAHYDRO-1H-PYRAZINO[2,1-A]ISOINDOLYLQUINOLINE COMPOUNDS FOR THE TREATMENT OF AUTOIMMUNE DISEASE | HOFFMANN LA ROCHE (CH) | 2023-09-20 | — | — | EP | disclosed |
| CN-113365984-A | LOX inhibitors | 癌症研究协会皇家癌症医院 | 2021-09-07 | — | — | CN | disclosed |
| EP-2619205-B1 | MONOHYDRATE OF AN AZAADAMANTANE DERIVATIVE | ABBVIE BAHAMAS LTD (BS) | 2017-05-17 | — | — | EP | disclosed |
| EP-2099795-B1 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBVIE BAHAMAS LTD (BS) | 2015-08-19 | — | — | EP | disclosed |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES | 2015-06-11 | — | — | US | disclosed |
| US-8987453-B2 | Azaadamantane derivatives and methods of use | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| EP-2231672-B1 | BIARYL SUBSTITUTED DIAZABICYCLOHEPTANE DERIVATIVES AS nAChR MODULATORS | ABBVIE INC (US) | 2014-12-17 | — | — | EP | disclosed |
| US-8853241-B2 | Biaryl substituted azabicyclic alkane derivatives | ABBVIE INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2431368-B1 | CNS active fused bicycloheterocycle substituted azabicyclic alkane derivatives | ABBVIE BAHAMAS LTD (BS) | 2014-08-27 | — | — | EP | disclosed |
| EP-2443122-B1 | DIAZAHOMOADAMANTANE DERIVATIVES AND METHODS OF USE THEREOF | ABBVIE INC (US) | 2014-03-05 | — | — | EP | disclosed |
| WO-2008079570-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008058096-A9 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LAB (US) | 2008-06-26 | — | — | WO | disclosed |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-26 | — | — | US | disclosed |
| EP-1926731-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2008-06-04 | — | — | EP | disclosed |
| WO-2008058096-A2 | AZAADAMANTANE DERIVATIVES AND THEIR USES AS NICOTINIC ACETYLCHOLINE RECEPTORS LIGANDS | ABBOTT LABORATORIES (US) | 2008-05-15 | — | — | WO | disclosed |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | ABBVIE INC. | 2008-02-21 | — | — | US | disclosed |
| WO-2007038058-A2 | AMINO-AZA-ADAMANTANE DERIVATIVES AND METHODS OF USE | ABBOTT LABORATORIES (US) | 2007-04-05 | — | — | WO | disclosed |
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | ABBOTT LABORATORIES | 2007-03-29 | — | — | US | disclosed |
| EP-1144413-B1 | 2,5-DIAZABICYCLO 2.2.1]HEPTANE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USES | SANOFI SYNTHELABO (FR) | 2004-03-17 | — | — | EP | disclosed |
| US-6635645-B1 | Nicotinic receptors dysfunction | SANOFI-SYNTHELABO (FR) | 2003-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072892-A1 | Amino-aza-adamantane derivatives and methods of use | CHRNA7, CHRNA5, CHRNA1 | CHRNB2 20/4885CHRNA4 7/4885CHRNA3 5/4885 |
| US-20080153860-A1 | SPIROCYCLIC AZAADAMANTANE DERIVATIVES AND METHODS OF USE | NR3C2, REN, GNE | CHRNB2 3613/4885CHRNA4 2292/4885CHRNA3 2144/4885 |
| US-20080045539-A1 | FUSED BICYCLOHETEROCYCLE SUBSTITUTED AZABICYCLIC ALKANE DERIVATIVES | MALT1, BMP2, ALKBH2 | CHRNB2 2585/4885CHRNA4 3022/4885CHRNA3 2174/4885 |
| US-20150158867-A1 | AZAADAMANTANE DERIVATIVES AND METHODS OF USE | GNE, CYP3A5, UGT1A4 | CHRNB2 1813/4885CHRNA4 960/4885CHRNA3 954/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.